An Evaluation of a Dynamic Web-Based Visualization of Community Immunity
4 de marzo de 2021 actualizado por: Laval University
This study is a PhD project conducted by Ms. Hina Hakim, supervised by Dr. Holly O. Witteman, PhD, and co-supervised Dr. Daniel Reinharz, professors and researchers at the Faculty of Medicine at Laval University.
The purpose of this study is to evaluate the effects of visualization conveying the concept of community immunity or herd immunity on risk perception (towards individual, family, community and vulnerable people in communities) (primary outcome) and on emotions, attitudes, knowledge, and behavioural intentions (secondary outcomes).
Descripción general del estudio
Estado
Desconocido
Condiciones
Descripción detallada
Visualization is a powerful communication mechanism that uses pre-attentive processing to communicate large amounts of information rapidly in understandable and compelling ways (Healey and Enns 2012). A systematic review demonstrates that there are some interventions available for conveying the concept of community immunity, and very few evaluate interventions for their effects on vaccine intentions and uptake as well as their precursors, such as knowledge, attitudes, knowledge and none on emotions (Hakim et al. 2018).
The purpose of this study is to evaluate the effects of visualization conveying the concept of community immunity on risk perception (to individual, family, community and vulnerable people in communities) (primary outcome) and on emotions, attitudes, knowledge, and behavioural intentions (secondary outcomes).
Tipo de estudio
Intervencionista
Inscripción (Anticipado)
5440
Fase
- No aplica
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Estudio Contacto
- Nombre: Holly Witteman, PhD
- Número de teléfono: 403981 418-656-2131
- Correo electrónico: holly.witteman.1@ulaval.ca
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
18 años y mayores (Adulto, Adulto Mayor)
Acepta Voluntarios Saludables
Sí
Géneros elegibles para el estudio
Todos
Descripción
Inclusion Criteria:
- Members of the general population in Canada
- At least 18 years old
- Able to provide free and informed consent
- Able to read and understand French or English
- Able to use a computer
Exclusion Criteria:
- No internet access
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Investigación de servicios de salud
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación factorial
- Enmascaramiento: Único
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Sin intervención: controlgeneric
No intervention provided.
Participant answers outcome questions about an unnamed vaccine-preventable disease.
English and French.
|
|
|
Sin intervención: controlmeasles
No intervention provided.
Participant answers outcome questions about measles.
English and French.
|
|
|
Sin intervención: controlpertussis
No intervention provided.
Participant answers outcome questions about pertussis.
English and French.
|
|
|
Sin intervención: controlflu
No intervention provided.
Participant answers outcome questions about flu.
English and French.
|
|
|
Experimental: herdimmgeneric
Web-based application (main intervention) provided.
Participant answers outcome questions about an unnamed vaccine-preventable disease.
English and French.
|
In this visualization participants can build their own avatar representing themselves and 8 other avatars representing people around them, like their family or coworkers.
Our visualization then uses these avatars in a brief narrated video explaining how herd immunity works.
|
|
Experimental: herdimmmeasles
Web-based application (main intervention) provided.
Participant answers outcome questions about measles.
English and French.
|
In this visualization participants can build their own avatar representing themselves and 8 other avatars representing people around them, like their family or coworkers.
Our visualization then uses these avatars in a brief narrated video explaining how herd immunity works.
|
|
Experimental: herdimmpertussis
Web-based application (main intervention) provided.
Participant answers outcome questions about pertussis.
English and French.
|
In this visualization participants can build their own avatar representing themselves and 8 other avatars representing people around them, like their family or coworkers.
Our visualization then uses these avatars in a brief narrated video explaining how herd immunity works.
|
|
Experimental: herdimmflu
Web-based application (main intervention) provided.
Participant answers outcome questions about flu.
English and French.
|
In this visualization participants can build their own avatar representing themselves and 8 other avatars representing people around them, like their family or coworkers.
Our visualization then uses these avatars in a brief narrated video explaining how herd immunity works.
|
|
Comparador activo: robertkochgeneric
Web-based application (comparator) provided.
Participant answers outcome questions about an unnamed vaccine-preventable disease.
English only.
|
A web-based application showing how herd immunity works in general: http://rocs.hu-berlin.de/D3/herd/
|
|
Comparador activo: sbsnewsgeneric
Video (comparator) provided.
Participant answers outcome questions about an unnamed vaccine-preventable disease.
English only.
|
A video showing how herd immunity works in general: https://www.sbs.com.au/news/two-sydney-babies-too-young-to-be-vaccinated-infected-with-measles
|
|
Comparador activo: guardianmeasles
Video (comparator) provided.
Participant answers outcome questions about measles.
English only.
|
A screen capture of an interactive visualization: https://www.theguardian.com/society/ng-interactive/2015/feb/05/-sp-watch-how-measles-outbreak-spreads-when-kids-get-vaccinated
|
|
Comparador activo: theotheredmundmeasles
Video (comparator) provided.
Participant answers outcome questions about measles.
English only.
|
A gif showing measles spreading through populations with differing levels of vaccine coverage: https://imgur.com/gallery/8M7q8#J7LANQ4
|
|
Comparador activo: publichealthagencycanadaflu
Video (comparator) provided.
Participant answers outcome questions about flu.
English and French.
|
A video showing how herd immunity works in the context of influenza: https://www.canada.ca/fr/sante-publique/services/video/la-grippe-n-en-passez-pas-les-maux.html
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Risk perception
Periodo de tiempo: immediately after intervention or control
|
6 ad hoc questions assessing risk perception
|
immediately after intervention or control
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
emotions, attitudes, knowledge, and behavioural intentions
Periodo de tiempo: immediately after intervention or control
|
ad hoc questions and 5C scale (Betsch et al.)
|
immediately after intervention or control
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio (Anticipado)
1 de marzo de 2021
Finalización primaria (Anticipado)
1 de mayo de 2021
Finalización del estudio (Anticipado)
1 de diciembre de 2021
Fechas de registro del estudio
Enviado por primera vez
4 de marzo de 2021
Primero enviado que cumplió con los criterios de control de calidad
4 de marzo de 2021
Publicado por primera vez (Actual)
9 de marzo de 2021
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
9 de marzo de 2021
Última actualización enviada que cumplió con los criterios de control de calidad
4 de marzo de 2021
Última verificación
1 de marzo de 2021
Más información
Términos relacionados con este estudio
Otros números de identificación del estudio
- herdimm
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
SÍ
Descripción del plan IPD
Anonymized data (answers to questions in the survey including socio-demographic information) will be deposited in a public repository (Dataverse de l'Université Laval (Laval University)) which will allow data sharing with the scientific community.
No information that would allow anyone to identify a person will be deposited in this public repository.
Study protocol and statistical analysis plan have been deposited in Open Science Framework.
Marco de tiempo para compartir IPD
As soon as possible upon completion of the study and posting of a preprint with results.
Criterios de acceso compartido de IPD
Freely available.
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
- SAVIA
- CIF
- CÓDIGO_ANALÍTICO
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
No
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
No
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .